Gateway

Gateway Biotechnology is a clinical-stage biopharmaceutical company dedicated to the development of therapies for hearing loss and related auditory disorders. The company's pipeline focuses on noise-induced hearing loss (NIHL) and cisplatin-induced hearing loss (CIHL), utilizing otoprotective small molecules to prevent damage to the inner ear's hair cells. Gateway's lead programs, GW-001 and GW-002, are currently in Phase 2 clinical development, addressing significant unmet needs in otology. By repurposing and optimizing known compounds, the company aims to provide the first FDA-approved pharmacological treatments for these prevalent conditions.